[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Cisplatin(CDDP), combined with 5-fluorouracil, is considered one of the most active chemotherapeutic combinations in the treatment of patients with squamous cell carcinoma of the head and neck(SCCHN)and is accepted today as a standard regimen. But second-line chemotherapy for platinum-pretreated patients has not yet been established. Eighteen patients with recurrent SCCHN were treated using docetaxel (TXT) and irinotecan (CPT-11). All of them had been pretreated with platinum included regimen. In principle, our regimen consisted of TXT(50-60 mg/m(2), day 1) and CPT-11(60-90 mg/m(2), day 1, 8, 15). The adverse events were significant, including 13(72.2%)of grade 3 and 4 neutropenia, but acceptable. Seventeen patients were eligible for evaluation of response. Two complete responses (CR; 11.8%)and 6 partial responses (PR; 35.3%)were observed with an overall response rate of 47.1%. Patients pretreated with TXT had a 25.0% response rate (1 PR and 3 progressive disease). We conclude that the combination of TXT and CPT-11 is a worthwhile treatment for platinum-pretreated SCCHN as a 2nd-line-chemotherapy.
Sakoda
Takema
T
Dept. of Otolaryngology, Rinku General Medical Center Izumisano Municipal Hospital, Japan.
Morizane
Rie
R
Nosaka
Aya
A
Nakahara
Kei
K
Fukutsuji
Kenji
K
Yamanishi
Mie
M
Ikeda
Hiroki
H
Shibano
Akira
A
Enomoto
Tadao
T
Kitano
Hiroya
H
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000627:therapeutic use*; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*
D043823:Taxoids; D000077143:Docetaxel; D010984:Platinum; D000077146:Irinotecan; D002166:Camptothecin